Literature DB >> 24320502

Repopulation of interacting tumor cells during fractionated radiotherapy: stochastic modeling of the tumor control probability.

Hatim Fakir1, Lynn Hlatky, Huamin Li, Rainer Sachs.   

Abstract

PURPOSE: Optimal treatment planning for fractionated external beam radiation therapy requires inputs from radiobiology based on recent thinking about the "five Rs" (repopulation, radiosensitivity, reoxygenation, redistribution, and repair). The need is especially acute for the newer, often individualized, protocols made feasible by progress in image guided radiation therapy and dose conformity. Current stochastic tumor control probability (TCP) models incorporating tumor repopulation effects consider "stem-like cancer cells" (SLCC) to be independent, but the authors here propose that SLCC-SLCC interactions may be significant. The authors present a new stochastic TCP model for repopulating SLCC interacting within microenvironmental niches. Our approach is meant mainly for comparing similar protocols. It aims at practical generalizations of previous mathematical models.
METHODS: The authors consider protocols with complete sublethal damage repair between fractions. The authors use customized open-source software and recent mathematical approaches from stochastic process theory for calculating the time-dependent SLCC number and thereby estimating SLCC eradication probabilities. As specific numerical examples, the authors consider predicted TCP results for a 2 Gy per fraction, 60 Gy protocol compared to 64 Gy protocols involving early or late boosts in a limited volume to some fractions.
RESULTS: In sample calculations with linear quadratic parameters α = 0.3 per Gy, α∕β = 10 Gy, boosting is predicted to raise TCP from a dismal 14.5% observed in some older protocols for advanced NSCLC to above 70%. This prediction is robust as regards: (a) the assumed values of parameters other than α and (b) the choice of models for intraniche SLCC-SLCC interactions. However, α = 0.03 per Gy leads to a prediction of almost no improvement when boosting.
CONCLUSIONS: The predicted efficacy of moderate boosts depends sensitively on α. Presumably, the larger values of α are the ones appropriate for individualized treatment protocols, with the smaller values relevant only to protocols for a heterogeneous patient population. On that assumption, boosting is predicted to be highly effective. Front boosting, apart from practical advantages and a possible advantage as regards iatrogenic second cancers, also probably gives a slightly higher TCP than back boosting. If the total number of SLCC at the start of treatment can be measured even roughly, it will provide a highly sensitive way of discriminating between various models and parameter choices. Updated mathematical methods for calculating repopulation allow credible generalizations of earlier results.

Entities:  

Mesh:

Year:  2013        PMID: 24320502      PMCID: PMC3843751          DOI: 10.1118/1.4829495

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  36 in total

1.  Radiation carcinogenesis modelling for risk of treatment-related second tumours following radiotherapy.

Authors:  K A Lindsay; E G Wheldon; C Deehan; T E Wheldon
Journal:  Br J Radiol       Date:  2001-06       Impact factor: 3.039

2.  A new view of radiation-induced cancer.

Authors:  I Shuryak; R K Sachs; D J Brenner
Journal:  Radiat Prot Dosimetry       Date:  2010-11-27       Impact factor: 0.972

3.  How well is the probability of tumor cure after fractionated irradiation described by Poisson statistics?

Authors:  S L Tucker; H D Thames; J M Taylor
Journal:  Radiat Res       Date:  1990-12       Impact factor: 2.841

Review 4.  Tumor control probability in radiation treatment.

Authors:  Marco Zaider; Leonid Hanin
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

5.  Genes and regulatory pathways involved in persistence of dormant micro-tumors.

Authors:  Nava Almog
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 6.  Cell production rates in human tissues and tumours and their significance. Part II: clinical data.

Authors:  D A Rew; G D Wilson
Journal:  Eur J Surg Oncol       Date:  2000-06       Impact factor: 4.424

7.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; J Y Douillard; M Tarayre; M J Lacombe-Terrier; A Laplanche
Journal:  Lung Cancer       Date:  1994-03       Impact factor: 5.705

Review 8.  Stem cells and their implications for colorectal cancer.

Authors:  Sebastian S Zeki; Trevor A Graham; Nicholas A Wright
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

9.  Improved models of tumour cure.

Authors:  S L Tucker; J M Taylor
Journal:  Int J Radiat Biol       Date:  1996-11       Impact factor: 2.694

10.  Second cancers after fractionated radiotherapy: stochastic population dynamics effects.

Authors:  Rainer K Sachs; Igor Shuryak; David Brenner; Hatim Fakir; Lynn Hlatky; Philip Hahnfeldt
Journal:  J Theor Biol       Date:  2007-08-12       Impact factor: 2.691

View more
  3 in total

1.  Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example.

Authors:  Tomas Radivoyevitch; Nopphon Siranart; Lynn Hlatky; Rainer Sachs
Journal:  AAPS J       Date:  2015-02-07       Impact factor: 4.009

2.  Tumour repopulation and the role of abortive division in squamous cell carcinomas during chemotherapy.

Authors:  L G Marcu
Journal:  Cell Prolif       Date:  2014-05-13       Impact factor: 6.831

3.  Dequalinium blocks macrophage-induced metastasis following local radiation.

Authors:  Michael Timaner; Rotem Bril; Orit Kaidar-Person; Chen Rachman-Tzemah; Dror Alishekevitz; Ruslana Kotsofruk; Valeria Miller; Alexander Nevelsky; Shahar Daniel; Ziv Raviv; Susan A Rotenberg; Yuval Shaked
Journal:  Oncotarget       Date:  2015-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.